SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

PF-06649751

Item No. 33556

CAS Registry No.:	1643489-24-0
Formal Name:	1,5-dimethyl-6-[2-methyl-4-[[3-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]-2,4(1H,3H)-pyrimidinedione
Synonym:	CVL-751
MF:	$C_{19}H_{16}F_3N_3O_3$
FW:	391.3
Purity:	≥98%
UV/Vis.:	λ_{max}: 273 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

PF-06649751 is supplied as a crystalline solid. A stock solution may be made by dissolving the PF-06649751 in the solvent of choice, which should be purged with an inert gas. PF-06649751 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of PF-06649751 in ethanol is approximately 2 mg/ml and approximately 30 mg/ml in DMSO and DMF.

PF-06649751 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, PF-06649751 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. PF-06649751 has a solubility of approximately 0.05 mg/ml in a 1:20 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

PF-06649751 is a dopamine D_1 and D_5 receptor partial agonist.[1] It increases locomotor activity and reduces a global parkinsonian disability score in a macaque model of Parkinson's disease induced by MPTP when administered at a dose of 0.04 mg/kg.

Reference

1. Young, D., Popiolek, M., Trapa, P., *et al.* D1 agonist improved movement of parkinsonian nonhuman primates with limited dyskinesia side effects. *ACS Chem. Neurosci.* **11(4)**, 560-566 (2020).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM